MariMed Reports Q1 Net Loss of $3.8M on $39.5M Revenue, Adjusted EBITDA at $3.6M
MRMD sits 31% above its 52-week low of $0.064.
Summary
MariMed Inc. announced its first-quarter 2026 financial results, reporting a net loss of $3.8 million and an adjusted net loss of $3.2 million. This follows the wider net loss reported in the company's 2025 10-K, indicating continued challenges to achieving profitability. The company generated $39.5 million in revenue and achieved $3.6 million in adjusted EBITDA, with an adjusted EBITDA margin of 9%. While positive adjusted EBITDA is a key metric, the persistent net losses are a significant concern for investors. Traders will closely monitor future reports for a clear path to sustained net profitability.
At the time of this announcement, MRMD was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $33.5M. The 52-week trading range was $0.06 to $0.23. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.